EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Inclusion Criteria: * Patients with diagnosis of haemophilia A, treated with KOGENATE Bayer/FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE Bayer/FS. For pretreated patients with more than 100 exposure days an inhibitor assessment within three months prior to enrollment should be available; for pretreated patients with less than 100 exposure days an inhibitor assessment at baseline should be available. Exclusion Criteria: * Exclusion criteria must be read in conjunction with the local product information.